Literature DB >> 16107510

Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

D Paran1, J Chapman, A D Korczyn, O Elkayam, O Hilkevich, G B Groozman, D Levartovsky, I Litinsky, D Caspi, Y Segev, V E Drory.   

Abstract

BACKGROUND: The CNS manifestations of the antiphospholipid syndrome (APS) can mimic multiple sclerosis both clinically and radiologically.
OBJECTIVE: To compare evoked potential studies in APS patients and patients with multiple sclerosis with similar neurological disability.
METHODS: 30 APS patients with CNS manifestations and 33 patients with definite multiple sclerosis and similar neurological disability underwent studies of visual evoked potentials (VEP), somatosensory evoked potentials (SSEP) in the upper and lower limbs (UL, LL), and sympathetic skin responses (SSR) in the upper and lower limbs.
RESULTS: The neurological manifestations in the APS patients included stroke (n = 17), transient ischaemic attacks (n = 10), and severe headache with multiple white matter lesions on brain MRI (n = 3). Abnormal SSEP (LL), and SSR (UL; LL) were seen in APS patients (37%, 27%, and 30%, respectively) but VEP and UL SSEP were rarely abnormal (10% and 6%, respectively in APS v 58% and 33% in multiple sclerosis; p = 0.0005, p = 0.008). Mean VEP latencies were more prolonged in multiple sclerosis (116 ms v 101 ms, p<0.001). Only one APS patient had abnormal findings in all three evoked potential studies, compared with seven patients in the multiple sclerosis group (p = 0.04)
CONCLUSIONS: Abnormal VEPs are uncommon in APS in contrast to multiple sclerosis. Coexisting abnormalities in all other evoked potentials were similarly rare in APS. In patients with brain MRI findings compatible either with multiple sclerosis or APS, normal evoked potential tests, and especially a normal VEP, may support the diagnosis of APS.

Entities:  

Mesh:

Year:  2005        PMID: 16107510      PMCID: PMC1798093          DOI: 10.1136/ard.2005.040352

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

Review 2.  Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature.

Authors:  R Cervera; R A Asherson; J Font; M Tikly; L Pallarés; A Chamorro; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1997-05       Impact factor: 1.889

3.  A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus.

Authors:  S Menon; E Jameson-Shortall; S P Newman; M R Hall-Craggs; R Chinn; D A Isenberg
Journal:  Arthritis Rheum       Date:  1999-04

4.  Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy.

Authors:  D Verrot; M San-Marco; C Dravet; P Genton; P Disdier; G Bolla; J R Harle; L Reynaud; P J Weiller
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

5.  Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?

Authors:  J W IJdo; A M Conti-Kelly; P Greco; M Abedi; M Amos; J M Provenzale; T P Greco
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

Authors:  J Chapman; M Cohen-Armon; Y Shoenfeld; A D Korczyn
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.

Authors:  S R Levine; R L Brey; K L Sawaya; L Salowich-Palm; J Kokkinos; B Kostrzema; M Perry; S Havstad; J Carey
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

8.  A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?

Authors:  D Karussis; R R Leker; A Ashkenazi; O Abramsky
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

9.  Tests of autonomic dysfunction in patients with multiple sclerosis.

Authors:  V E Drory; P F Nisipeanu; A D Kroczyn
Journal:  Acta Neurol Scand       Date:  1995-11       Impact factor: 3.209

10.  1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis.

Authors:  S M Leary; C A Davie; G J Parker; V L Stevenson; L Wang; G J Barker; D H Miller; A J Thompson
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

View more
  2 in total

1.  An uncommon illness with a rare presentation: neurosurgical management of ADEM with tumefactive demyelination in children.

Authors:  Matthew VanLandingham; William Hanigan; Vetta Vedanarayanan; Jonathan Fratkin
Journal:  Childs Nerv Syst       Date:  2009-12-01       Impact factor: 1.475

2.  MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis.

Authors:  Milena Stosic; Julian Ambrus; Neeta Garg; Bianca Weinstock-Guttman; Murali Ramanathan; Bernadette Kalman; Alireza Minagar; Frederick E Munschauer; Timothy M Galey; Sara Hussein; Rohit Bakshi; Robert Zivadinov
Journal:  J Neurol       Date:  2009-07-26       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.